<DOC>
	<DOCNO>NCT00072215</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide , cisplatin , paclitaxel , vinblastine , work different way stop tumor cell divide stop grow die . It yet know whether ifosfamide cisplatin effective combine paclitaxel vinblastine treat germ cell tumor . PURPOSE : This randomized phase III trial study paclitaxel , ifosfamide , cisplatin see well work compare vinblastine , ifosfamide , cisplatin treat men progressive recurrent metastatic germ cell tumor .</brief_summary>
	<brief_title>Cisplatin Ifosfamide Combined With Either Paclitaxel Vinblastine Treating Men With Progressive Recurrent Metastatic Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival men progressive recurrent metastatic germ cell tumor treat paclitaxel , ifosfamide , cisplatin v vinblastine , ifosfamide , cisplatin second-line therapy . Secondary - Compare progression-free survival patient treat regimen . - Compare toxicity profile regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord prior complete response partial response negative marker least 6 month ( yes v ) relapse least 2 year complete first-line chemotherapy germ cell tumor ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive paclitaxel IV 24 hour day 1 cisplatin IV 20-30 minute ifosfamide IV 30 minute day 2-5 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 7-18 OR pegfilgrastim SC within 24-72 hour completion chemotherapy . - Arm II : Patients receive vinblastine IV day 1 2 cisplatin IV 20-30 minute ifosfamide IV 30 minute day 1-5 . Patients also receive G-CSF SC day 7-18 OR pegfilgrastim arm I . In arm , treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients follow every 2 month 2 year , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm germ cell tumor ( GCT ) , include 1 follow primary tumor site : Seminoma Testis Retroperitoneum Mediastinum Other extragonadal site Nonseminoma Testis Retroperitoneum Other extragonadal site No tumor mediastinum Must evidence metastatic disease , include either follow : Unidimensionally measurable lesion At least 20 mm conventional technique ( e.g. , physical exam clinically palpable lymph node superficial skin lesion chest xray clearly define lung lesion surround aerated lung ) OR least 10 mm spiral CT scan MRI Nonmeasurable lesion , include follow : Small lesion Bone lesions Pleural pericardial effusion Ascites Irradiated lesion , unless progression document radiotherapy Progressive recurrent disease meeting least 1 follow criterion : Measurable progressive disease Biopsyproven residual disease Persistently elevate rise ßhuman chorionic gonadotropin ( HCG ) alphafetoprotein ( AFP ) titer clear cause elevation Previously treat 1 1 regimen comprise etoposide cisplatin without bleomycin AND exhibit clinical resistance least 1 follow condition therapy* : Progressive GCT partial response firstline therapy Relapse complete response ( CR ) firstline therapy , include partial response ( PR ) surgically convert CR Second testicular primary evidence metastasis firstline therapy Relapse adjuvant chemotherapy NOTE : *Patients fail achieve PR CR firstline therapy evidence rise marker new disease within 4 week firstline therapy eligible PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal* ( ULN ) AST ALT ≤ 2.5 time ULN* NOTE : *Unless hepatic metastasis present Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Other Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior doseintensive therapy stem cell replacement Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy No prior paclitaxel No prior docetaxel No prior ifosfamide No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy Concurrent sequential radiotherapy brain metastasis allow No concurrent palliative radiotherapy Surgery See Disease Characteristics Concurrent surgery brain metastasis allow Other Recovered prior therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
</DOC>